Ghent University Academic Bibliography

Show Sort by

Your filters: cql: parent exact "ALLERGY"

Add to list
- Journal Article
- A1
Dupilumab improves health-related quality of life in severe chronic rhinosinusitis with nasal polyps

Stella E Lee, Claire Hopkins, Joaquim Mullol, Jérôme Msihid, Isabelle Guillemin, Nikhil Amin, Leda P Mannent, Yongtao Li, Shahid Siddiqui and Asif H. Khan (UGent)

(2023) ALLERGY.
Add to list
- Journal Article
- A1
- open access
Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses : EAACI task force on eicosanoids consensus report in times of COVID-19

Milena Sokolowska, G. Enrico Rovati, Zuzana Diamant, Eva Untersmayr, Jurgen Schwarze, Zuzanna Łukasik (UGent) , Florentina Sava, Alba Angelina, Oscar Palomares, Cezmi Akdis, et al.

(2022) ALLERGY. 77(8). p.2337-2354
Add to list
COVID‐19 vaccination with BNT162b2 and ChAdOx1 vaccines has the potential to induce nasal neutralizing antibodies

Jozefien Declercq (UGent) , Els Tobback (UGent) , Stijn Vanhee (UGent) , Natalie De Ruyck (UGent) , Sarah Gerlo (UGent) , Philippe Gevaert (UGent) and Linos Vandekerckhove (UGent)

(2022) ALLERGY. 77(1). p.304-307
Add to list
- Journal Article
- A1
- open access
Physical activity in asthma control and its immune modulatory effect in asthmatic preschoolers

Debbie J. Maurer, Chengyao Liu, Paraskevi Xepapadaki, Barbara Stanic, Claus Bachert (UGent) , Susetta Finotto, Ya‐Dong Gao, Anna Graser, Tuomas Jartti, Walter Kistler, et al.

(2022) ALLERGY. 77(4). p.1216-1230
Add to list
- Journal Article
- A1
- open access
Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID‐ERD : results from two randomized placebo‐controlled phase 3 trials

Joaquim Mullol, Tanya M. Laidlaw, Claus Bachert (UGent) , Leda P. Mannent, G. Walter Canonica, Joseph K. Han, Jorge F. Maspero, Cesar Picado, Nadia Daizadeh, Benjamin Ortiz, et al.

(2022) ALLERGY. 77(4). p.1231-1244
Add to list
- Journal Article
- A1
- open access
Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status

Shigeharu Fujieda, Shoji Matsune, Sachio Takeno, Nobuo Ohta, Mikiya Asako, Claus Bachert (UGent) , Tomoyuki Inoue, Yoshinori Takahashi, Hiroyuki Fujita, Yamo Deniz, et al.

(2022) ALLERGY. 77(1). p.186-196
Add to list
- Journal Article
- A1
- open access
Dupilumab improves health related quality of life : results from the phase 3 SINUS studies

Stella E Lee, Claire Hopkins, Joaquim Mullol, Jérôme Msihid, Isabelle Guillemin, Nikhil Amin, Leda P Mannent, Yongtao Li, Shahid Siddiqui, Chien Chia Chuang, et al.

(2022) ALLERGY. 77(7). p.2211-2221
Add to list
The Charcot-Leyden crystal protein Galectin-10 is not a major determinant of human regulatory T-cell function

Rebeca Arroyo-Hornero, Helena Catharine Aegerter (UGent) , Ibrahim Hamad, Beatriz Corte-Real, Katrien Staes (UGent) , Bas van Der Woning, Kenneth Verstraete (UGent) , Savvas Savvides (UGent) , Bart Lambrecht (UGent) and Markus Kleinewietfeld

(2022) ALLERGY. 77(9). p.2818-2821
Add to list
- Conference Paper
- C3
Improvement in patient-reported ’taste’ and association with smell in dupilumab-treated severe chronic rhinosinusitis with nasal polyps patients from the SINUS-24 and SINUS-52 trials

AT Peters, ZM Soler, Kern Rc, E Heffler, JF Maspero, L Crampette, S Fujieda, AP Lane, H Zhang, S. Nash, et al.

(2021) ALLERGY. In Allergy 76(supplement 110). p.301-302
Add to list
- Journal Article
- A1
- open access
ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020)

Jean Bousquet, Marek Jutel, Cezmi A. Akdis, Ludger Klimek, Oliver Pfaar, Kari C. Nadeau, Thomas Eiwegger, Anna Bedbrook, Ignacio J. Ansotegui, Josep M. Anto, et al.

(2021) ALLERGY. 76(3). p.689-697

Academic Bibliography

Dupilumab improves health-related quality of life in severe chronic rhinosinusitis with nasal polyps

Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses : EAACI task force on eicosanoids consensus report in times of COVID-19

COVID‐19 vaccination with BNT162b2 and ChAdOx1 vaccines has the potential to induce nasal neutralizing antibodies

Physical activity in asthma control and its immune modulatory effect in asthmatic preschoolers

Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID‐ERD : results from two randomized placebo‐controlled phase 3 trials

Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status

Dupilumab improves health related quality of life : results from the phase 3 SINUS studies

The Charcot-Leyden crystal protein Galectin-10 is not a major determinant of human regulatory T-cell function

Improvement in patient-reported ’taste’ and association with smell in dupilumab-treated severe chronic rhinosinusitis with nasal polyps patients from the SINUS-24 and SINUS-52 trials

ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020)

Contents

Support

Contact